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Abstract
Aims Arrhythmogenic cardiomyopathy (AC) is characterized by right ventricular (RV) dilatation and dysfunction and is often
seen in combination with tricuspid regurgitation (TR). The aim of this study was to investigate the characteristics and prognos-
tic implications of TR in patients with AC.
Methods and results Clinical, echocardiographic, and cardiac magnetic resonance data of 52 patients with AC fulfilling 2010
Task Force criteria in a single centre were retrospectively evaluated. TR in AC was classified as no/mild, moderate, or severe on
the basis of the current guidelines. Significant TR was defined as at least moderate TR. The primary endpoint was a composite
of death, heart transplantation, and tricuspid valve surgery. There were seven patients (13.4%) with moderate TR and 13 pa-
tients (25.0%) with severe TR at initial diagnosis. Patients with severe TR showed a higher prevalence of atrial fibrillation and a
higher mean NT-pro-BNP than other groups (68%, P = 0.013; 2423 ± 1578 pg/mL, P < 0.001, respectively). Patients with sig-
nificant TR revealed a higher incidence of heart failure at initial presentation than did those without significant TR (30.0 vs.
3.1%, P = 0.022). Patients with severe TR showed significantly larger RV and lower RV and left ventricular functional parame-
ters. During a mean follow-up of 4.2 years, three groups classified by TR severity considerably discriminated clinical outcomes
(log rank P = 0.019). Patients with significant TR had a poorer prognosis than those with no or mild TR (42.9 vs. 3.1%, log rank
P = 0.005). Cox regression analysis showed significant TR as an independent prognostic factor (hazard ratio 11.41, 95% confi-
dential interval 1.30–99.92, P = 0.028).
Conclusions Significant TR at initial diagnosis in patients with AC is a poor prognostic factor.
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Introduction
Arrhythmogenic cardiomyopathy (AC) is an inherited cardio-
myopathy that predominantly affects the right ventricle
(RV) and is associated with ventricular arrhythmias, heart fail-
ure (HF), and sudden cardiac death.1,2 RV structural and func-
tional changes in AC may also lead to the development of
functional tricuspid regurgitation (TR).3 Significant TR may
contribute to worsened HF by both increased RV filling pres-
sure and lowered RV forward stroke volume.4
Severe TR is associated with a poor prognosis indepen-
dent of age and biventricular systolic function.5 The prog-
nostic implications of moderate-to-severe TR in mitral
valve disease,6–8 aortic stenosis,9,10 and chronic HF11 have
been demonstrated. However, the prevalence, characteris-
tics, and prognostic implications of TR in patients with AC
are still unclear, although one prior study suggested a po-
tential significance of TR for clinical outcome.4 Therefore,
the aims of this study were to evaluate the prevalence of
TR in AC, to define clinical and echocardiographic
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characteristics of patients with AC according to TR severity,




We retrospectively investigated 52 patients (39 men, mean
age 47 ± 19 years) with AC who met the 2010 Revised Task
Force Criteria12 and who were available for follow-up in Sev-
erance Cardiovascular Hospital from March 2005 to May
2018. Family history, previous documented ventricular ar-
rhythmias, age, co-morbidities, and clinical presentation at
onset were systematically assessed. All patients underwent
physical examination, laboratory tests, 12-lead electrocardio-
gram, and transthoracic echocardiography. Cardiac magnetic
resonance imaging or endomyocardial biopsy was performed
in selected cases according to physician decisions. Among 52
patients, 41 patients (79%) underwent cardiac magnetic reso-
nance imaging and 15 patients (29%) underwent
endomyocardial biopsy at initial diagnosis. The Institutional
Review Board of Severance Hospital approved the present
study, which was conducted in compliance with the Declara-
tion of Helsinki.
Echocardiography
Standard two-dimensional and Doppler measurements were
performed following the American Society of Echocardiogra-
phy guidelines.13 TR severity was classified as no/mild, mod-
erate, or severe according to the integration of multiple
parameters recommended in current guidelines.14 Significant
TR was defined as moderate or severe TR.
RV systolic dysfunction was defined by two-dimensional
echocardiography. RV area measurements were taken from
the apical four-chamber focused RV view at end-diastole
and end-systole, and RV fractional area change (FAC) was
calculated as the ratio between the difference of the
end-diastolic and end-systolic RV areas and the
end-diastolic area.13 RV FAC < 33% (<2 standard deviations
from normal values) defines RV systolic dysfunction, while
RV FAC ≤ 25% (≤3 standard deviations from normal values)
defines severe RV systolic dysfunction.4 Left ventricular (LV)
dysfunction was defined when LV ejection fraction was
lower than 50% and/or as the presence of akinesia or
dyskinesia.4 Echocardiographic data were carefully reviewed
by two experienced cardiologists who were blinded to
clinical data.
Follow-up and outcomes
The primary endpoint was a composite of death, heart trans-
plantation, and tricuspid valve surgery. Additionally, appropri-
ate shock with implantable cardioverter defibrillator (ICD)
and hospitalization due to worsened HF were analysed as
the second endpoints. Surgical treatments including heart
transplantation and tricuspid valve surgery were determined
at the discretion of attending physicians. The appropriateness
of ICD shocks was judged by an electrophysiologist who
reviewed intracardiac electrocardiograms. Worsened HF was
defined by signs and symptoms such as dyspnoea, rales,
and ankle oedema, as well as the need for diuretic agents, va-
sodilators, or positive inotropic drugs.
Statistical analysis
Continuous variables were expressed as mean ± standard de-
viation. Categorical variables were expressed as number (per-
centage). Comparisons between groups were performed
using standard λ2 tests for categorical variables and paired
t-tests for continuous variables. Univariate and multivariate
logistic regression analyses were performed. Survival curves
were constructed using the Kaplan–Meier method, and com-
parisons were made using the log-rank test. All statistical
analyses were performed using SPSS Statistics, software ver-
sion 25.0 (IBM, Armonk, NY, USA); P-values _x0003C; 0.05
were considered statistically significant.
Results
Characteristics of patients with arrhythmogenic
right ventricular cardiomyopathy combined with
tricuspid regurgitation
Table 1 shows baseline characteristics according to initial TR
severity. At the time of diagnosis, seven patients (13.5%)
had moderate TR and 13 patients (25.0%) had severe TR by
echocardiography. Therefore, moderate-to-severe TR, which
was classified as significant TR, was observed in 20 patients
(38.5%) with arrhythmogenic right ventricular cardiomyopa-
thy (ARVC).
There were no significant differences in age, sex propor-
tion, and body mass index among the three groups. The inci-
dence of diabetes mellitus and atrial fibrillation was
significantly higher in patients with severe TR than in the
other groups. However, there were no differences in the
prevalence of hypertension and coronary artery disease. On
laboratory findings, NT-pro-BNP was significantly greater in
the severe TR group than in the other groups despite no dif-
ferences in renal function or haemoglobin level.
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In terms of initial clinical presentation of AC, ventricular ar-
rhythmia was the most common in all groups. Sudden cardiac
death tended to be more prevalent in patients with no/mild
TR or moderate TR than in those with severe TR. Few patients
had HF in the no or mild TR group, but it was significantly
more common in the moderate and severe TR groups
(P = 0.022) (Figure 1).
Echocardiographic characteristics are presented in Table
2. Severe TR groups showed significantly lower LV ejection
fraction than the other groups. Patients with severe TR
had a higher E/e′ than patients with no/mild TR. As ex-
pected, RV dimensions assessed on parasternal views and
RV focused views were significantly larger in the severe TR
group than were variables in the other groups. Interestingly,
the difference in mid-RV dimension were apparent between
patients with moderate TR and those with severe TR. RV
functional variables such as FAC, tricuspid annular plane sys-
tolic excursion, and S′ velocity at the tricuspid annulus were
significantly lower than in other groups. LV dysfunction was
prevalent in the severe TR group, but there was no
difference in the incidence of RV dysfunction among the
three groups.
Cardiac magnetic resonance findings are presented in Ta-
ble 3. The data showed consistent echocardiographic data
in terms of chamber size and function. The RV dimension
and volume were larger in the severe TR group, and the LV
and RV ejection fractions were lower. However, there was
no significant difference between the three groups in
myocardial tissue characteristics such as late gadolinium
enhancement and fat deposition.
Table 1 Baseline characteristics
No/mild TR (n = 32) Moderate TR (n = 7) Severe TR (n = 13) P-value
Age, years 44 ± 19 57 ± 14 50 ± 19 0.220
Male, n (%) 25 (78) 5 (71) 9 (69) 0.800
Body mass index, kg/m2 23.8 ± 3.2 24.3 ± 2.6 24.4 ± 3.3 0.875
Hypertension, n (%) 9 (28) 1 (14) 2 (15) 0.550
Diabetes mellitus, n (%) 1 (3) 1 (14) 5 (38) 0.007
CAD, n (%) 4 (13) 0 (0) 4 (31) 0.147
AF, n (%) 9 (28) 5 (71) 9 (69)* 0.013
Systolic BP, mmHg 115 ± 13 121 ± 13 117 ± 17 0.604
Diastolic BP, mmHg 72 ± 11 72 ± 15 72 ± 15 1.000
Haemoglobin, g/dL 13.8 ± 2.0 14.1 ± 1.7 13.9 ± 2.1 0.921
eGFR, mL/min/1.73 m2 79.8 ± 18.3 83.3 ± 8.8 82.5 ± 11.3 0.814
NT-pro-BNP, pg/mL 688 ± 741 608 ± 595 2423 ± 1578*,** <0.001
ICD, n (%) 16 (50) 5 (71) 6 (46) 0.525
Initial presentation
SCD, n (%) 8 (25) 2 (29) 1 (8) 0.382
VT/VF, n (%) 10 (31) 3 (43) 4 (31) 0.827
Syncope, n (%) 5 (16) 0 (0) 1 (8) 0.444
Heart failure, n (%) 1 (3) 2 (29)* 4 (31)* 0.022
Others, n (%) 8 (25) 0 (0) 3 (23) 0.334
AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate;
ICD, implantable cardioverter defibrillator; NT-pro-BNP, N-terminal pro brain natriuretic peptide; SCD, sudden cardiac death; TR, tricuspid
regurgitation; VF, ventricular fibrillation; VT, ventricular tachycardia.
*P < 0.05 compared with no/mild TR group.
**P < 0.05 compared with moderate TR group.
FIGURE 1 Initial clinical presentations of patients with arrhythmogenic cardiomyopathy (AC) according to tricuspid regurgitation (TR) severity. (A) Sud-
den cardiac death. (B) Ventricular arrhythmia. (C) Heart failure.
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Clinical outcomes according to tricuspid
regurgitation severity in arrhythmogenic right
ventricular cardiomyopathy
Clinical outcomes are shown in Table 4. There were signifi-
cantly more heart transplantation and tricuspid valve surger-
ies in the severe TR group than in other groups. The
composite of death, HT, and tricuspid valve surgery was sig-
nificantly more prevalent in the severe TR group than the
other groups. However, secondary endpoints such as
appropriate ICD shock and hospitalization due to worsened
HF were not significantly different between subgroups. Sur-
vival analysis was performed on the composite of death,
heart transplantation, and tricuspid valve surgery during the
Table 2 Echocardiographic characteristics
No/mild TR (n = 32) Moderate TR (n = 7) Severe TR (n = 13) P-value
Characteristics of left chambers
LV EDD, mm 50.0 ± 5.1 46.9 ± 6.2 48.7 ± 5.9 0.345
LV ESD, mm 35.8 ± 6.3 32.6 ± 6.0 38.4 ± 7.9 0.181
LV EF, % 56.8 ± 11.5 64.0 ± 7.6 43.1 ± 16.2*,** 0.001
LV mass index, g/m2 87.3 ± 24.6 88.8 ± 23.9 88.5 ± 28.0 0.984
LA volume index, mL/m2 27.0 ± 11.8 36.4 ± 12.2 30.5 ± 18.7 0.253
E/e′ 11.1 ± 6.1 13.4 ± 7.2 16.5 ± 7.5* 0.135
Characteristics of right chambers
RVOTd (PLAX), mm 33.2 ± 6.6 36.4 ± 9.1 49.9 ± 13.8*,** <0.001
RVOTd (PSAX), mm 32.5 ± 7.0 35.1 ± 8.3 45.5 ± 12.5*,** <0.001
RV EDA, mm2 27.6 ± 6.0 29.9 ± 11.2 31.0 ± 9.9* <0.001
RV ESA, mm2 19.6 ± 5.4 20.9 ± 10.1 31.3 ± 11.7* <0.001
Basal RV, mm 36.2 ± 5.3 38.9 ± 5.4 43.4 ± 7.9* 0.003
Mid-RV, mm 40.0 ± 7.4 42.6 ± 10.3 54.8 ± 11.7*,** <0.001
RV length, mm 80.5 ± 8.1 81.1 ± 13.9 86.2 ± 9.3 0.179
FAC, % 29.3 ± 9.6 26.7 ± 12.9 22.9 ± 8.6* 0.147
TAPSE, mm 17.7 ± 5.9 22.8 ± 5.1 11.5 ± 1.9*,** 0.001
S′ velocity, cm/s 9.9 ± 3.2 12.0 ± 2.8 7.4 ± 1.6*,** 0.004
RA area, mm2 16.2 ± 4.8 22.4 ± 6.8 35.1 ± 19.0*,** <0.001
TV annulus, mm 33.6 ± 5.2 41.2 ± 18.2* 43.6 ± 8.5* 0.003
TR VCW, mm 3.0 ± 1.3 4.7 ± 0.5* 10.8 ± 4.6*,** <0.001
TR velocity, m/s 2.2 ± 0.2 2.6 ± 0.5 2.0 ± 0.4*,** 0.001
RVSP, mmHg 26.6 ± 5.5 37.7 ± 15.3* 31.9 ± 5.9* 0.002
Ventricular dysfunction
LV dysfunction, n (%) 7 (22) 0 (0) 7 (54)* 0.020
RV dysfunction, n (%) 19 (59) 4 (57) 10 (77) 0.505
Both, n (%) 7 (22) 0 (0) 5 (39) 0.145
E/e′, ratio of early diastolic mitral inflow velocity to early diastolic mitral annular tissue velocity; e′, early diastolic mitral annular tissue; EDA,
end-diastolic area; EDD, end-diastolic dimension; EF, ejection fraction; ESA, end-diastolic area; ESD, end-systolic dimension; FAC, frac-
tional area change; LAVI, left atrial volume index; LV, left ventricular; RA, right atrium; RV, right ventricular; RVOTd (PLAX), right ventricular
outflow track diameter at parasternal long axis view; RVOTd (PSAX), right ventricular outflow track diameter at parasternal short axis view;
RVSP, right ventricular systolic pressure; S′, tricuspid annulus systolic tissue; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid
regurgitation; TV, tricuspid valve; VCW, vena contracta width.
*P < 0.05 compared with no or mild TR group.
**P < 0.05 compared with moderate TR group.
Table 3 Cardiac magnetic resonance findings
No/mild TR (n = 27) Moderate TR (n = 5) Severe TR (n = 9) P-value
LV EDV, mL 176 ± 47 143 ± 37 154 ± 51 0.250
LV ESV, mL 85 ± 41 64 ± 31 85 ± 45 0.559
LV EF, % 53 ± 11 58 ± 11 43 ± 22 0.133
LV LGE, n (%) 6 (22) 3 (60) 4 (44) 0.325
RV EDV, mL 227 ± 51 203 ± 115 357 ± 134*,** 0.001
RV ESV, mL 136 ± 46 108 ± 73 292 ± 146*,** <0.001
RV EF, % 41 ± 12 50 ± 9 23 ± 11*,** 0.001
RV LGE, n (%) 14 (52) 3 (60) 8 (89) 0.353
Fat deposition, n (%) 6 (22) 0 (0) 1 (11) 0.762
EDV, end-diastolic volume; ESV, end-systolic volume; LGE, late gadolinium enhancement; LV, left ventricular; RV, right ventricular; TR, tri-
cuspid regurgitation.
*P < 0.05 compared with no or mild TR group.
**P < 0.05 compared with moderate TR group.
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mean follow-up duration of 4.2 years. The severe TR group
had significantly lower event-free survival than other groups
(log rank P = 0.019, Figure 2A). When divided into signifi-
cant TR group or not, the significant TR group also showed
significantly lower event-free survival than the not signifi-
cant TR group (log rank P = 0.005, Figure 2B). Cox
regression analysis showed that significant TR was an inde-
pendent prognostic factor after controlling for age at diag-
nosis, sex, presence of diabetes mellitus, atrial fibrillation,
LV dysfunction, and severe RV dysfunction (hazard ratio
11.41, 95% confidential interval 1.30–99.92, P = 0.028)
(Table 5).
Table 4 Clinical outcomes
No/mild TR (n = 32) Moderate TR (n = 7) Severe TR (n = 13) P-value
Primary endpoints
Death 1 (3.1) 1 (14.3) 1 (7.7) 0.488
Heart transplantation 0 (0.0) 0 (0.0) 4 (30.8)* 0.002
Tricuspid valve surgery 0 (0.0) 1 (14.3)* 2 (15.4)* 0.078
Secondary endpoints
Appropriate shock of ICD 13 (40.6) 3 (42.9) 3 (23.1) 0.505
Hospitalization due to worsened HF 8 (25.0) 3 (42.9) 5 (38.5) 0.511
HF, heart failure; ICD, implantable cardioverter defibrillator; TR, tricuspid regurgitation.
*P < 0.05 compared with no or mild TR group.
FIGURE 2 Kaplan–Meier analysis of freedom from primary endpoints. (A) Comparison in three groups classified by tricuspid regurgitation (TR) severity.
(B). Comparison in two groups according to presence of significant TR.
Table 5 Cox proportional regression analysis for primary endpoints
Primary endpoints
Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Age 0.99 0.95–1.03 0.532 0.99 0.94–1.04 0.649
Female sex 0.96 0.20–4.67 0.963 0.86 0.11–6.66 0.884
Diabetes mellitus 0.77 0.16–3.79 0.743 0.07 0.00–1.43 0.084
AF 2.78 0.57–13.52 0.206 5.52 0.95–31.89 0.057
LV dysfunction 1.84 0.51–6.68 0.351 3.25 0.45–23.46 0.243
Severe RV dysfunction 2.71 0.69–10.61 0.151 3.87 0.59–25.34 0.158
Significant TR 9.61 1.21–76.16 0.032 11.41 1.30–99.92 0.028
AF, atrial fibrillation; CI, confidential interval; HR, hazard ratio; LV, left ventricular; RV, right ventricular; TR, tricuspid regurgitation.
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Discussion
The principal findings of this study are that (i) the prevalence
of significant TR at initial diagnosis was not uncommon in pa-
tients with AC; (ii) patients with significant TR showed worse
clinical outcome than those without; and (iii) presence of sig-
nificant TR was an independent prognostic factor after con-
trolling age, sex, atrial fibrillation, and LV or RV dysfunction.
These results suggest that patients with AC require careful
follow-up to assess TR because TR severity provides prognos-
tic information in this specific population.
In this study, the prevalence of significant TR, defined as
moderate or severe TR, was 38.5%. The prevalence of TR in
ARVC has been shown at varying levels in previous studies.
In a multicentre cohort of 96 AC patients, significant TR was
15% in the overall population.4 The higher prevalence of sig-
nificant TR in our study might be explained by some differ-
ences in baseline characteristics and definition of significant
TR. Our study population was older and tended to have more
co-morbidities than the previous cohort population. A previ-
ous study also reported the prevalence of significant TR as
14% in 70 patients with AC.15 Compared with this previous
study, our study population showed more advanced RV re-
modelling and functional impairment, which may influence
the higher prevalence of significant TR.
TR that occurs despite structurally normal leaflets is termed
functional TR. Because AC is characterized by RV dilatation
and dysfunction, significant functional TR can be expected in
a considerable number of patients in the course of AC disease
progression. In a previous study regarding the mechanisms of
functional TR, RV remodelling patterns are not uniform.16 Idi-
opathic functional TR associated with aging or atrial fibrillation
showed wider RV base and annulus, while functional TR with
pulmonary hypertension revealed only modest annular dilata-
tion with leaflet tethering above the annular level and RV
lengthening.16 In the present study, AC patients with severe
TR demonstrated modest annular and basal RV dilatation
but significantly wider mid-RV dimension and RV outflow tract
diameters than did the other groups. However, the RV length
in three groups was not different. RV morphologic changes in
AC frequently occur at the inferior-sub-tricuspid and mid-RV
outflow track.3 As the disease progresses, global RV dilatation
and dysfunction often lead to the development of functional
TR without pulmonary hypertension.3
In our study, patients with severe TR showed higher NT-pro-
BNP and HF manifestations. Interestingly, patients with mod-
erate TR also presented with a higher incidence of HF at initial
presentation. Even in patients with clinically significant TR, TR
is often asymptomatic. Theoretically, lesser degrees of TR
could have adverse hemodynamic effects because the RV is al-
ready damaged in patients with AC. Therefore, the presence of
moderate TR combined with RV dysfunction may contribute to
the HF and poor clinical outcomes of this study.
TR is an important prognostic factor in various diseases.
Neuhold et al.11 studied the impact of moderate and severe
TR for endpoints such as death, heart transplantation, and
LV assist device implantation in 576 patients with HF. TR
was significantly associated with poor outcomes in patients
with mild or moderate LV dysfunction. TR has been suggested
as a predictive factor of survival, HF, and functional capacity
in patients with mitral valve disease.17 It has been reported
that when RV dysfunction had already progressed, the prog-
nosis was poor even if TR was corrected. Thus, TR is associ-
ated with poor prognosis in various cardiac conditions,
especially if it is combined with ventricular dysfunction. How-
ever, there are scant data regarding TR in AC. This is a mean-
ingful study showing the prognostic implications of significant
TR by focusing on TR in AC. Previous studies have more fo-
cused on arrhythmic risks or myocardial function in specific
cardiomyopathies.2 Several studies have shown that patients
with more extensive RV and/or LV disease have a higher ar-
rhythmic risk and poor clinical outcomes.4,15,18 In a 10 year
registry study, significant TR was shown to be an independent
predictor for cardiac death or heart transplantation.4 Further-
more, recent studies suggested clinical implications of atrial
arrhythmias in patients with AC not only for inappropriate
ICD shocks but also for increased risk of HF and death.19,20
TR may initiate a cycle that propagates further dilatation
and dysfunction in both the RV and right atrium, which in-
duces atrial arrhythmia and worsening TR.
The results of this study have several clinical implications.
First, patients with significant TR at initial diagnosis of AC
should be carefully treated with medication, rehabilitation,
and lifestyle modification to improve clinical outcomes. Sec-
ond, comprehensive echocardiographic follow-up should fo-
cus on both RV function and changes in TR severity to
optimally time heart transplantation or intervention for sig-
nificant TR. In this study, three patients underwent tricuspid
valve surgery. However, surgical correction of significant TR
is particularly challenging because of the higher risks of post-
operative HF and arrhythmic events. In the near future, trans-
catheter intervention to reduce TR severity may be applied in
patients with AC.
Limitations
First, this was a single-centre retrospective study in a tertiary
referral centre. Therefore, the prevalence of significant TR
observed in this study might be overestimated because of a
higher proportion of patients with advanced AC in a spectrum
of the disease. Although dynamic changes in TR severity dur-
ing the follow-up might affect the clinical course, the present
study did not include the longitudinal echocardiographic
data. Second, this study was limited to Korean patients with
AC. To interpret and apply the main results to all races, fur-
ther studies in another population are warranted. However,
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we believe that our study is meaningful because most data
for patients with AC have originated only from Caucasian
populations. Third, genetic mutations were not studied in this
population. Because a recent study demonstrated a potential
association between desmoglein-2 mutation carriers and
end-stage HF,21 further genetic studies about HF and TR are
warranted.
Conclusions
TR is common in patients with AC. Because echocardiographic
evaluation of TR severity in patients with AC provides prog-
nostic information, the presence of significant TR in patients
with AC should be closely monitored.
Clinical perspective
Arrhythmogenic cardiomyopathy is an inherited cardiomyop-
athy that predominantly affects the RV. RV structural and
functional changes in AC may also lead to the development
of functional TR. Significant TR may contribute to worsened
HF by both increased RV filling pressure and lowered RV for-
ward stroke volume. In this study, we found that the preva-
lence of significant TR at initial diagnosis was not
uncommon in patients with AC. This study added important
data on the prognostic value of significant TR in patients with
AC. It may be suggested that patients with AC require careful
follow-up to assess TR because TR severity provides prognos-
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